Dasatinib Tablet, Film Coated
NDC 72603-925
Product Information
Dasatinib is a ANDA-approved product labeled by Northstar Rxllc. This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It is supplied as a white tablet, film coated for oral administration. This product entry covers the primary NDC 72603-925 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
OVAL (C48345)
TRIANGLE (C48353)
11 MM
9 MM
10 MM
5C
L623
L624
L625
Code Structure Chart
Product Details
What is NDC 72603-925?
What are the uses of this product?
What are Active Ingredients of this product?
- DASATINIB 80 mg/1 - A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- DASATINIB (UNII: RBZ1571X5H)
- DASATINIB ANHYDROUS (UNII: X78UG0A0RN) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.